Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirelizumab Plus Chemotherapy in Gastric Cancer After D2 Resection
NCT05844371Phase 2Unknown
- Sponsor
- Yixing People's Hospital
- Start
- Apr 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC), sponsored by Yixing People's Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05844371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844371.